



HAL
open science

Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF₃) derivatives as potential anticancer agents

Xianran He, Min Zhong, Shaolei Li, Xiaolong Li, Yiyan Li, Zhongtang Li, Yangguang Gao, Fei Ding, Dan Wen, Yuchen Lei, et al.

► **To cite this version:**

Xianran He, Min Zhong, Shaolei Li, Xiaolong Li, Yiyan Li, et al.. Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and SeCF₃) derivatives as potential anticancer agents. *European Journal of Medicinal Chemistry*, 2020, 208, pp.112864. 10.1016/j.ejmech.2020.112864 . hal-03240011

HAL Id: hal-03240011

<https://hal.sorbonne-universite.fr/hal-03240011>

Submitted on 27 May 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Synthesis and biological evaluation of organoselenium (NSAIDs-SeCN and**
2 **SeCF₃) derivatives as potential anticancer agents**

3
4 Xianran He^a, Min Zhong^b, Shaolei Li^c, Xiaolong Li^c, Yiyan Li^d, Zhongtang Li^d,
5 Yangguang Gao^a, Fei Ding^a, Dan Wen^a, Yuchen Lei^b, Yongmin Zhang^{a, e, *}

6
7 ^a *Institute for Interdisciplinary Research, Jiangnan University, Wuhan Economic and*
8 *Technological Development Zone, Wuhan 430056, China*

9 ^b *School of Chemical and Environmental Engineering, Jiangnan University, Wuhan Economic*
10 *and Technological Development Zone, Wuhan 430056, China*

11 ^c *Shenzhen Fushan Biological Technology Co., Ltd, Kexing Science Park A1 1005, Nanshan*
12 *Zone, Shenzhen 518057, China*

13 ^d *State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences,*
14 *Peking University, Beijing 100191, China*

15 ^e *Institut Parisien de Chimie Moléculaire, UMR 8232, CNRS, Sorbonne Université, 4 Place*
16 *Jussieu, 75005 Paris, France*

17 *Corresponding author: yongmin.zhang@upmc.fr

1 **Abstract:**

2 A series of organoselenium compounds based on the hybridization of
3 nonsteroidal antiinflammatory drugs (NSAIDs) scaffolds and Se functionalities
4 (-SeCN and -SeCF₃) were synthesized and characterized, and evaluated against four
5 types of cancer cell lines, SW480 (human colon adenocarcinoma cells), HeLa (human
6 cervical cancer cells), A549 (human lung carcinoma cells), MCF-7 (human breast
7 adenocarcinoma cells). Interestingly, most of the investigated compounds showed
8 active in reducing the viability of different cancer cell lines. The most active
9 compound **3h** showed IC₅₀ values lower than 20 μM against the four cancer cell lines,
10 particularly to SW480 and MCF-7 with IC 50 values of 4.9 and 3.4 μM, respectively.
11 Furthermore, NSAIDs-SeCN derivatives (**2h** and **2i**) and NSAIDs-SeCF₃ derivatives
12 (**3h** and **3i**) were selected to investigate their ability to induce apoptosis in MCF-7
13 cells via modulation the expression of anti-apoptotic Bcl-2 protein, pro-inflammatory
14 cytokines (IL-2) and proapoptotic caspase-3 protein. Moreover, the redox properties
15 of the synthesized organoselenium candidates were conducted by 2,
16 2-didiphenyl-1-picrylhydrazyl (DPPH), bleomycin dependent DNA damage and
17 glutathione peroxidase (GPx)-like assays. Taken together, these NSAIDs-Se
18 candidates could provide promising new lead derivatives for further potential
19 anticancer drug development.

20

21

22

23

24 **Keywords:** NSAIDs, selenocyanates, trifluoromethyl selenides, anticancer

25

26

1 **1. Introduction**


2 Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of drugs widely
3 used clinically to treat a variety of inflammatory conditions including pain associated
4 with arthritis in the world [1, 2]. On the other side, a growing body of studies
5 addressed the chemo-preventive activities of NSAIDs, such as aspirin (ASA) and
6 other NSAIDs can be used as chemo-preventive agents, especially in colorectal cancer
7 (CRC) [3, 4]. Other studies suggest that daily dosing of ASA decreases the risk of a
8 great variety of cancer types, including lung, breast, skin, pancreas, and ovarian
9 cancers[5-8]. Additionally, a growing body of studies addressed the anticancer
10 activities of NSAIDs [9, 10], although their exact molecular mechanism has remained
11 elusive.

12 Selenium (Se), a unique trace element plays a crucial role in human health and
13 disease [11]. Organic selenium compounds with diverse functional groups, including
14 selenoesters [12], selenocyanates [13, 14], methylseleninic acid [15],
15 isoselenocyanates [16], diselenides [17] and endocyclic selenium [18] have been
16 reported to exhibit anticancer activity (**Fig 1**). Among these compounds, organic
17 selenocyanates have emerged as a promising candidate during the past two decades.
18 The first selenocyanate described was the 1,4-phenylenebis(methylene)selenocyanate
19 (p-XSC), which proved to be effective against prostate and oral carcinoma cells [19].
20 Recently, growing interest has been paid to bioactive organic trifluoromethyl sulfides
21 (-SCF₃) because of its unique properties which were brought by the
22 trifluoromethylthio moiety including high lipophilicity (Hansch's constant $p = 1.44$),
23 metabolic stability and electron withdrawing effect [20, 21]. In contrast to
24 trifluoromethyl sulfides group, trifluoromethyl selenides (-SeCF₃) group is suspected
25 to have more lipophilic and stable group. However, the biological property of SeCF₃
26 attached molecular is hardly documented at the moment: in the past few years,
27 particular attention has focused on the synthetic methods to obtain
28 trifluoromethylselenylated molecules [22-26].

29 In this report, considering the chemo-preventive effects of NSAIDs and the
30 anticancer activity of organic selenium compounds, along with the reports that

1 support the modification of NSAIDs scaffolds with Se functionalities [27, 28], several
 2 NSAIDs-SeCN and NSAIDs-SeCF₃ derivatives were designed with a general model
 3 consist of three essential fragments in their molecular: i) NSAIDs fragment; ii)
 4 electron donating group; iii) functional group bearing the Se atom (**Fig2**). The
 5 anticancer activity of the compounds was assessed using human cancer cell lines,
 6 SW480 (human colon adenocarcinoma cells), HeLa (human cervical cancer cells),
 7 A549 (human lung carcinoma cells), MCF-7 (human breast adenocarcinoma cells).
 8 Furthermore, the antioxidant potential of the compounds was investigated by
 9 employing DPPH, bleomycin-dependent DNA damage and GPx-like assays. Finally,
 10 docking studies were applied as a preliminary prediction tool to estimate the
 11 drugability of the prepared NSAIDs-Se hybrid compounds.


12



13

14 **Fig. 1.** Organic selenium compounds with diverse functional groups previously
 15 reported to exhibit anticancer activity

16



17

18

Fig. 2. Structure of NSAIDs-Se derivatives

19


1
2
3
4
5
6
7
8
9
10
11
12
13

2. Results and Discussion

2.1. Chemistry

Herein we present the synthesis of novel families of NSAIDs-based selenoderivatives as potential anticancer agents: selenocyanates, trifluoromethyl selenides.

The synthesis of the NSAIDs-SeCN derivatives (**2a-2j**) was started from commercially available NSAIDs and 3-selenocyanatopropanamine hydrobromide (**1**) in the presence of EDCI and HOBT as condensation agent, in DMF as solvent and under a nitrogen atmosphere (Scheme 1) [29].



14

Scheme 1. (a) KSeCN, CH₃CN, 80°C, 18 h, 90%; (b) EDCI, HOBT, TEA, CH₂Cl₂/DMF, N₂, r.t. 0.5 h, 65%-80%; (c) TBAF, TMSCF₃, THF, rt, 6 h, 70%-85%.

15
16
17
18
Compound **1** was obtained by the nucleophilic substitution of -Br atom in 3-bromopropanamide hydrobromide by -SeCN, using KSeCN as nucleophilic

1 donor, in acetonitrile as solvent and under a nitrogen atmosphere (Scheme 1)
2 [30]. The trifluoromethyl selenide derivatives were obtained by conducting
3 corresponding selenocyanate derivative with trimethyl(trifluoromethyl)silane
4 (TMSCF₃) in the present of tetrabutylammonium fluoride (TBAF) as catalyst to afford
5 **3a-3j** [31] in good yields (yield ≥ 85%) (Scheme 1).

6

7 2.2. Cell viability assay

8 All the tested NSAIDs-Se derivatives reported in Scheme 1 were evaluated for
9 their anticancer activity towards human tumor cell lines derived from various human
10 cancer types: SW480 (human colon adenocarcinoma cells), HeLa (human cervical
11 cancer cells), A549 (human lung carcinoma cells), MCF-7 (human breast
12 adenocarcinoma cells). *In vitro* evaluation of anticancer activity was determined by
13 the MTT assay at three time points (24 h, 48 h and 72 h), following previously
14 published method of NSAID-Se hybrid compounds (selenocoxib-1 and its glutathione
15 conjugate) with little change [32].

16 As reported in Table 1, the selected patent NSAIDs (Sulindac, Indometacin and
17 ketoprofen) had no effect on cancer cell viability even in the maximum dose of 50 μM.
18 The IC₅₀ values obtained for the hybrid Se derivatives **2a**, **2d** and **3e**, showed that
19 introduction of the SeCN or SeCF₃ moiety in corresponding parent NSAIDs result in
20 the significant effect on cancer cell line [33]. From this observation, the present study
21 reports the synthesis of NSAIDs-Se derivatives bearing selenocyanates and
22 trifluoromethyl selenides scaffolds and their *in vitro* anticancer activity against the
23 same cell lines as used in Table 2.

24 An overview analysis of the IC₅₀ values obtained and summarized in Table 2
25 showed that all the compounds presented moderate effect against all four cancer cell
26 lines, while compounds **2a**, **2e**, **2h**, **2i**, **3a**, **3b**, **3d**, **3e**, **3g**, **3h** and **3i** were effective at
27 all time points. Furthermore, compounds **2h**, **2i**, **3h** and **3i** showed cytotoxic to
28 SW480 cells with IC₅₀ value below 10 μM. Compounds **3h** and **3i** exhibited cytotoxic
29 to MCF-7 cell lines with IC₅₀ value below 5 μM. *From the current cytotoxic activity*

1 experiment, all the compounds seem not selective to special cancer cell lines, further
 2 work will be performed to expand the scope of cancer cell lines to find selective
 3 cytotoxicity of these compounds.

4 Interestingly, the anticancer activity of NSAIDs-SeCF₃ derivatives (**3a-3j**) is
 5 better than corresponding NSAIDs-SeCN derivatives (**2a-2j**), maybe the increasing of
 6 lipophilicity increased anticancer activity for these NSAIDs-SeCF₃ derivatives [34].
 7 Among the tested compounds, it was determined that compounds **3h** and **3i** showed
 8 higher promising activities than other derivatives. Compound **3h** exhibited the most
 9 potent activity against all four cancer cell lines with IC₅₀ value below 20μM and with
 10 remarkable anticancer activity against MCF-7 (2.8 μM at 72 h) and SW480 (3.3 μM
 11 at 48 h).

12

13 **Table 1.** Cytotoxic activity expressed by IC₅₀ of NSAID-Se hybrid compounds (**2a**,
 14 **2d**, and **3e**) compared to their respective parent NSAIDs on different cancer cell lines

	IC ₅₀ (μM) ^a						
	h	2a	Sulindac	2d	indometacin	3e	ketoprofen
SW480	24	15.4±0.5	>50	16.3±1.2	>50	8.2±0.3	>50
	48	12.4±0.7	>50	18.2±1.2	>50	7.4±0.1	>50
	72	12.1±0.8	>50	14.2±1.3	>50	6.5±0.2	>50
HeLa	24	28.4±2.5	>50	32.1±11	>50	19.6±7	>50
	48	16.2±1.5	>50	24.4±6	>50	17.5±4	>50
	72	21.5±2.0	>50	19.6±5	>50	28.7±5	>50
A549	24	11.4±1.8	>50	28.5±4	>50	13.1±1.2	>50
	48	15.3±2.2	>50	31.2±6	>50	18.4±2.1	>50
	72	9.4±0.3	>50	>50	>50	22.6±2.6	>50
MCF-7	24	13.2±1.3	>50	28.3±3.2	>50	8.6±0.2	>50
	48	8.4±0.8	>50	>50	>50	9.3±0.3	>50
	72	11.3±1.1	>50	>50	>50	9.5±0.3	>50

15 ^a IC₅₀ values (±SD) of % cell viability determined by the MTT assay of three
 16 repetitions.

17

18 **Table 2.** Cytotoxic activity expressed by IC₅₀ of NSAID-Se hybrid compounds (**2a-2j**
 19 and **3a-3j**) on different cancer cell lines

Compd. No.	h	IC ₅₀ (μM) ^[a]			
		SW480	HeLa	A549	MCF-7
5-Fu ^[b]	24	15.3±0.6	20.6±3.5	25.3±3.6	8.5±0.5

	48	12.4±0.8	15.5±4.2	22.5±2.4	10.4±0.7
	72	13.1±1.4	12.7±3.4	17.3±1.3	12.6±0.8
2a	24	15.4±0.5	28.4±2.5	11.4±1.8	13.2±1.3
	48	12.4±0.7	16.2±1.5	15.3±2.2	8.4±0.8
	72	12.1±0.8	21.5±2.0	9.4±0.3	11.3±1.1
2b	24	23.2±1.1	36.2±8	23.5±9	22.4±3.2
	48	30.5±4	32.4±7	32.2±11	32.1±12.6
	72	21.7±5	15.9±8	>50	>50
2c	24	14.4±0.6	26.5±4	37.3±8	18.5±1.6
	48	9.7±0.4	34.3±6	>50	11.2±0.9
	72	13.2±0.5	>50	>50	7.9±0.5
2d	24	16.3±1.2	32.1±11	28.5±4	28.3±3.2
	48	18.2±1.2	24.4±6	31.2±6	>50
	72	14.2±1.3	19.6±5	>50	>50
2e	24	10.2±0.4	25.6±6	24.1±4	9.6±0.7
	48	8.4±0.2	18.5±7	28.4±5	11.3±0.9
	72	7.7±0.1	34.7±8	32.6±8	12.5±0.9
2f	24	12.0±3.1	21.5±5	32.2±2.5	28.3±5
	48	21.7±2.2	24.5±5	>50	27.1±4
	72	30.4±5.8	35.7±7	>50	>50
2g	24	19.5±1.6	26.8±3.2	28.4±6	35.2±5
	48	18.9±1.5	17.4±2.8	21.7±4	37.4±6
	72	20.6±1.2	28.5±6	36.6±9	>50
2h	24	8.9±0.4	13.5±1.2	24.4±2.6	12.1 ±0.6
	48	5.3±0.2	26.3±2.3	30.2±4	14.3±1.2
	72	6.4±0.2	29.3±2.5	28.5±3.2	16.5±1.4
2i	24	9.3±0.1	31.4±9	18.4±2.5	6.8 ±0.6
	48	7.4±0.3	28.4±5	22.6±3.3	8.6±0.8
	72	8.2±0.2	18.3±2.3	22.3±3.5	10.3±1.1
2j	24	25.2±1.4	38.2±11	26.1±5	14.2±0.4
	48	17.4±1.2	33.4±9	28.3±7	16.4±0.5
	72	24.7±2.3	>50	36.4±9	13.3±0.5
3a	24	13.4±0.4	24.3±2.3	9.4±1.5	8.2±0.2
	48	11.4±0.6	15.1±1.3	11.3±2.0	6.4±0.1
	72	10.1±1.2	19.4±2.1	7.4±0.3	10.4±0.6
3b	24	18.3±1.3	30.2±7	14.5±1.6	12.1±1.2
	48	24.4±2.4	28.4±6	23.2±2.2	17.1±2.0
	72	19.5±1.8	14.9±4	35.4±6	18.5±2.2
3c	24	12.4±0.3	24.5±2.2	27.3±2.8	8.5±0.3
	48	8.4±0.2	28.3±3.5	36.8±4	9.2±0.2
	72	10.3±0.3	>50	>50	6.9±0.1
3d	24	14.6±1.2	30.1±9	18.3±1.6	17.3±2.8
	48	16.4±1.3	21.4±5	26.5±2.9	26±3.1
	72	13.1±1.1	15.6±4	30.3±5	35±5

3e	24	8.2±0.3	19.6±7	13.1±1.2	8.6±0.2
	48	7.4±0.1	17.5±4	18.4±2.1	9.3±0.3
	72	6.5±0.2	28.7±5	22.6±2.6	9.5±0.3
3f	24	10.0±3.0	16.5±3.2	28.4±2.0	19.3±4
	48	15.7±4	22.5±4	33.5±2.4	22.1±5
	72	25.4±5	30.7±7	>50	35.5±7
3g	24	17.5±1.4	22.8±3.4	19.4±1.8	26.2±3.2
	48	14.5±1.7	14.4±2.5	17.7±1.6	28.4±3.5
	72	19.6±2.0	25.5±4	26.6±2.3	33.5±4
3h	24	4.9±0.2	11.5±1.0	9.4±1.1	3.4 ±0.1
	48	3.3±0.1	17.4±2.1	15.2±1.6	4.3±0.1
	72	4.2±0.1	19.7±2.2	18.5±2.3	2.8±0.1
3i	24	8.2±0.2	28.7±7	16.4±1.8	3.5±0.1
	48	7.2±0.1	26.3±5	18.6±3.0	4.2±0.2
	72	7.8±0.2	15.4±2.4	17.3±3.3	4.4±0.2
3j	24	22.2±2.4	33.2±9	18.1±1.5	7.2±0.4
	48	15.7±1.1	30.3±8	21.3±2.7	8.4±0.3
	72	19.7±2.2	>50	26.4±3.6	9.3±0.5

1 ^a IC₅₀ values (±SD) of % cell viability determined by the MTT assay of three
2 repetitions. ^b Standard benchmark compound.

3

4 2.3. Evaluation of Bcl-2, IL-2 and caspase-3 molecular biomarkers in MCF-7 cells.


5 Previous studies showed that potential death mechanism(s) of organoselenium
6 compounds may be due to apoptosis induction [35]. This was confirmed via the
7 detection of various cellular alterations (e.g., cell morphology, cell cycle delay, and
8 activation of caspase 3/7 and caspase 8) [36].

9 In order to explore the underlying mechanism for the reduced cell viability of the
10 synthesized compounds, the most promising NSAIDs-Se derivatives **2h**, **2i**, **3h** and **3i**
11 were selected and investigated their ability to induce apoptosis in MCF-7 cells via
12 modulation the expression of anti-apoptotic Bcl-2 protein, pro-inflammatory
13 cytokines (IL-2) and proapoptotic caspase-3 protein.


14 As shown in Fig 3, all the compounds were able to downregulate the expression
15 of Bcl-2 and upregulate the expression of IL-2 and Caspase-3 in MCF-7 cells
16 compared with untreated cells. Interestingly, compounds **3h** and **3i** downregulate over
17 50% the expression levels of Bcl-2 compared to untreated cells. Furthermore,
18 compound **2h** modulate the IL-2 level at most 1.5 fold increase in expression when

1 compared to the untreated control cells. Finally, compound **3i** exhibited a superior
2 activity increased the expression level of caspase-3 by 5-fold compared to untreated
3 cells. From the above results, it's likely that compounds **2h**, **2i**, **3h** and **3i** may induce
4 apoptosis to inhibit tumor cells growth, and in line with the underlying mechanism of
5 some organoselenium compounds which was reported to be effective against prostate
6 and oral carcinoma cells via the estimation of potential biomarkers [37].


7



35



36



37

38 **Fig. 3.** Protein expression levels of Bcl-2, IL-2 and caspase-3 in MCF-7 cells after 48
39 h incubation with compounds **2h**, **2i**, **3h** and **3i** at their respective IC_{50} s compared to
40 untreated cells.

41

42 2.4. Antioxidant assay

43 Reactive oxygen species (ROS) is a series of active oxygen clusters and are
44 produced in all aerobic cells. ROS is considered as a signal molecule that regulates a

1 variety of physiological processes. Various human diseases, including different types
2 of cancer, are associated with a disturbed intracellular redox balance and oxidative
3 stress (OS) [38]. Redox modulators play an important role in chemotherapeutic
4 potential antitumor agents [39].

5 Owing to the fact that a number of synthetic organoselenium compounds have
6 been synthesized for their use as redox-modulators in the last few years [40-42], the
7 antioxidant activity of the selected synthesized compounds are further estimated
8 employing different biochemical assays such as DPPH, bleomycin-dependent DNA
9 damage and Gpx-like assays [43, 44].

11 2.4.1. Radical scavenging capacity (DPPH) assay.

12 There are various methods which have been developed to provide fast prediction
13 of antioxidant of natural compounds [45], however, the DPPH chemical assay is
14 considered to be the rapid tools to evaluate the radical-scavenging activities of
15 nutritional products and organic selenides [46]. The antioxidant activity of a
16 compound is assessed by its ability to decolorize DPPH radical (purple color in
17 methanol) to DPPHH (colorless) and the corresponding radical-scavenging activity is
18 estimated by the decrease in the absorbance at 517 nm [47]. Vitamin C was used as a
19 positive control (**Table 3**).

20 As depicted in **Table 3**, NSAIDs-SeCF₃ derivatives **3h** and **3i** were the most
21 active compounds in this assay, demonstrating a good free-radical scavenging activity
22 compared to Vitamin C. The family of NSAIDs-SeCF₃ derivatives is better than the
23 corresponding NSAIDs-SeCN derivatives on this assay except for **the comparison of**
24 **2d and 3d**.

26 2.4.2. Bleomycin DNA damage assay.

27 Bleomycin (BLM) is a group of anti-neoplastic agents from *Streptomyces*
28 *verticillus*, it is believed to oxidize DNA and induces single and double strand breaks
29 [48]. The bleomycin-iron DNA damage assay has been routinely used as a
30 preliminary method to test potential of drugs and organic selenium compound [49, 50].

1 As shown in **Table 3**, compounds **2d**, **3b**, **3g** and **3i** induced DNA degradation
 2 significantly more than other tested compounds.

3

4 **Table 3.** Redox modulation activity of NSAID-Se hybrid compounds.


Compd. No.	DPPH		Bleomycin-dependent DNA damage assay
	Inhibition %	Fold	
Vitamin C	92.4±2.2	1	295±3.22
2a	21.2±1.8	0.2	76.5±0.65
2b	16.3±1.5	0.2	80.4±0.84
2c	26.5±2.6	0.3	62.9±0.43
2d	49.6±2.9	0.5	105.6±1.84
2e	30.4±1.4	0.3	75.5±0.62
2f	22.6±1.4	0.2	80.6±0.88
2g	24.5±1.5	0.3	92.1±0.78
2h	60.8±3.4	0.7	88.5±1.26
2i	52.1±2.3	0.6	95.6±1.44
3a	32.8±2.1	0.4	99.3±0.72
3b	40.5±2.8	0.4	104.5±2.23
3c	38.9±2.4	0.4	68.3±1.42
3d	25.8±1.4	0.3	97.6±1.63
3e	48.4±2.6	0.5	82.3±1.44
3f	37.2±2.0	0.4	90.7±1.28
3g	26.8±1.6	0.3	110.8±2.25
3h	68.7±2.2	0.7	92.7±1.62
3i	72.5±2.8	0.8	130.4±1.46

5

6 2.4.3. Glutathione peroxidase-like activity assay.

1 Glutathione peroxidase (GPx) is an important selenoenzyme found in humans
2 that is responsible for the reduction of toxic peroxides at the expense of glutathione
3 (GSH), an endogenous thiol [51, 52]. The potential antioxidant activity of all of the
4 NSAIDs-Se derivatives were estimated using NADPH-reductase coupled assay [53,
5 54]. The GPx activity of the synthesized compounds was estimated by the decrease in
6 absorbance (340 nm) due to the oxidation of NADPH to NADP⁺. Ebselen was used as
7 the positive control.

8 As shown in **Fig. 4**, compounds **2h**, **2i**, **3b**, **3e**, **3h** and **3i** displayed a GPx-like
9 activity better than other derivatives. Compound **3h** was the most active derivatives in
10 this assay, up to 3 fold to the GPx mimetic ebselen.



12 **Fig. 4.** GPx-like activity assay of NSAID-Se hybrid compounds in µM. Min⁻¹.

14 2.5. Docking Studies

15 Compound drugability against another selenium-contained enzyme, Thioredoxin
16 Reductase 1(TrxR1), was investigated *in silico* based on the previously revealed
17 binding mode of ethaselen featuring two selenenyl covalent bonds respectively with
18 Cys497 and Sec498 [55]. Here, we adopted a noncovalent docking method given that
19 binding modes of covalent ligands are mostly determined by noncovalent interactions.
20

21 Compound **2h**, **3h**, **3i** with promising antioxidant activity were docked into the
22 rat Sec498Cys mutant TrxR1 protein (PDB id: 1H6V) using Flexible Docking

1 Protocol as reported in the literature [56]. Distance between the selenium atom and
 2 either Cys497 or Cys498 with a 0.5 nm cut-off was used to assess the accessibility of
 3 the cysteine thiol attacking the selenide, according to the proximity rule of disulfide
 4 bonding [57]. For each tested compound, multiple binding poses were generated, the
 5 best of which was elected with balanced consideration of binding energy and spatial
 6 proximity to Cys497/Cys498.


7 Overall analysis of all potential poses, as shown in **Table 4**, gave an evaluation
 8 of the binding affinity and covalent reaction possibility, presenting compound **3h** as
 9 the most probable TrxR1 inhibitor with the highest average $-CDocker$ energy and
 10 greater likeliness of selenium-cysteine interaction. Compared with **3h**, apart from
 11 bearing the same scaffold, compound **2h** possesses a cyano group that, through
 12 hydrogen bonding, directly orients the reactive selenium atom, in most cases, away
 13 from Cys497/Cys498, which accounts for the increased average Se- S_{Cys498} distance.
 14 Docking performance of compound **3i** is rather unsatisfying probably due to a less
 15 compatible NSAID core with the binding cavity. Nonetheless, **3i** is somehow the most
 16 competent one to interfere with Cys497.

17 For each top pose in **Fig. 5**, access of the selenium atom to the reactive
 18 Cys497/Cys498 is facilitated with the assistance of hydrogen bonds between the
 19 carbonyl oxygen and neighboring residues (e.g. Ser404), as well as π - π stacking of the
 20 benzene ring and aromatic residues (e.g. Trp 407).

Table 4. Analysis of the flexible docking poses clustered by featured compound

	Average -CDocker energy /kcal·mol ⁻¹ (Mean±S.D.)	Average Se- S_{Cys498} Distance ^a (d_{498}) /Å (Mean±S.D.)	Average Se- S_{Cys497} Distance ^a (d_{497})/Å (Mean±S.D.)	Number (percentage ^{a,b}) of potentially reactive complexes ^c : Total/Cys498-reacting/ Cys497-reacting ^d	Average -CDocker energy of potentially reactive complexes /kcal·mol ⁻¹ (Mean±S.D.)
3h	35.68±4.20	8.39±4.00	11.62±3.08	10(19.6) / 10(19.6) / 0	37.06±2.41
2h	33.75±4.25	8.99±2.69	11.4±2.06	5(12.7) / 4(10.5) / 1(2.2)	34.34±2.27
3i	26.26±3.70	8.85±4.20	10.65±3.49	8(19.4) / 5(12.8) / 3(6.6)	25.50±2.68

a. energy weighted; b. in terms of all poses of the corresponding compound; c,d. Complexes with d_{498} or d_{497} no more than 0.5Å, referred to as Cys498-reacting and Cys497-reacting complexes, respectively.



1

2 **Fig. 5.** Top pose of each compound (ball-and-stick in black) and cysteine497/498
 3 (thick tube in purple). A. Top pose with respect to both **3h** and Cys498. The carbonyl
 4 oxygen of **3h** is hydrogen-bonded with Ser404. (–CDOCKER ENERGY = 39.24
 5 kcal/mol, distance Se-S_{Cys498} = 3.98 Å.) B. Top pose of **2h**, showing that the carbonyl
 6 oxygen of **2h** interacts with Cys498 and Gly499 through hydrogen bonds with their
 7 amino groups. Π - π stacking between the benzene ring of **2h** and His472 also
 8 contributes to the binding, while the cyano group oriented towards Ser404 acts as a
 9 downside. (–CDOCKER ENERGY = 37.14 kcal/mol, distance Se-S_{Cys498} = 5.29 Å.) C.
 10 Top pose of **3i**, with no significant interaction detected. (–CDOCKER ENERGY =
 11 30.95 kcal/mol, distance Se-S_{Cys498} = 4.22 Å.) D. Top pose regarding Cys497,
 12 featured by compound **2h** that shares hydrogen bond and π - π interactions with Trp407.
 13 (–CDOCKER ENERGY = 30.20 kcal/mol, distance Se-S_{Cys497} = 3.80 Å.)

14

15 3. Conclusions

16 In summary, the present study reports the synthesis of new organoselenium
 17 derivatives including NSAIDs scaffolds and Se functionalities (-SeCN and -SeCF₃),
 18 Compound **3h** exhibited the most potent activity in MTT assay with remarkable
 19 anticancer activity against MCF-7 (2.8 μ M at 72 h) and SW480 (3.3 μ M at 48 h).
 20 Compounds **2h**, **2i**, **3h** and **3i** were selected to verify if organic selenides can induce

1 apoptosis in MCF-7 cells by modulating the expression of the Bcl-2, IL-2 and
2 caspase-3 molecular biomarkers, the selected compounds were able to downregulate
3 the expression of Bcl-2 and upregulate the expression of IL-2 and Caspase-3 in
4 MCF-7 cells compared with untreated cells. Furthermore, some of the synthesized
5 NSAIDs-Se hybrid compounds (e.g., **2d**, **2h**, **2i**, **3b**, **3d**, **3e**, **3g**, **3h**, **3i**) exhibited
6 antioxidant activity in antioxidant evaluation including DPPH, bleomycin-dependent
7 DNA damage and Gpx-like assays.

8 Overall, considering the potency of these NSAIDs-Se derivatives on cancer cell
9 viability, antioxidant activity and docking study, it appears that introduction of
10 selenocyanate (-SeCN) or trifluoromethyl selenides (-SeCF₃) moiety to some NSAIDs
11 could serve as a promising launch point for the further design of this type of
12 NSAIDs-Se anticancer agents.

13

14 **4. Materials and methods**

15 4.1 Materials

16 All chemical reagents for the synthesis of the compounds were purchased from
17 Macklin (Shanghai, China) or TCI (Shanghai, China) and used without further
18 purification unless stated otherwise. TLCs were performed on aluminium pre-coated
19 sheets (E. Merck Silica gel 60 F254). Melting points (uncorrected) were recorded on
20 an Electrothermal apparatus. ¹H (400 MHz), ¹³C (100 MHz) NMR and ¹⁹F (376 MHz)
21 spectra were recorded at 25°C on a Bruker Avance 400 MHz spectrometer **with 5 mm**
22 **PABBO probe**. Chemical shifts (δ) are reported in parts per million (ppm) and the
23 coupling constants(*J*) are expressed in Hertz (Hz). Mass analysis was recorded on an
24 ESI source mass detector (Thermo LCQ FLEET). HRMS spectrometry was
25 performed on a SCIEX, TripleTOF 5600+, operating in ionization mode.

26

27 4.2. Experimental procedures

28 *4.2.1. Procedure for the synthesis of compound 1*

29 To a solution of 3-bromopropan-1-amine hydrobromide (3g, 13.7 mmol) in
30 anhydrous acetonitrile (40 mL) was added KSeCN (1.97 g, 13.7mmol). The mixture

1 was stirred at 80°C for 18 hours. Then the mixture was cooled to 25°C and filtered.
2 The filter cake was washed with acetonitrile (5mL×2) and dried under vacuum to
3 obtain the brown solid (3.1g yield = 91%). The isolated solid was used without
4 purification for further reactions.

5

6 4.2.2. General procedure for the synthesis of compounds 2a-2j

7 To a solution of patent NSAIDs (1.0 eq) in DCM (5 mL) and DMF (5 mL) was
8 added EDCI (1.2 eq.), HOBT (1.2 eq.) and TEA (3.0 eq.). The mixture was stirred at
9 25°C for 30 minutes under nitrogen atmosphere. Then 3-selenocyanatopropanamine
10 hydrobromide (1.2 eq.) was added into the mixture. The mixture was stirred at 25°C
11 for 16 hrs under inert atmosphere. TLC showed the reaction was complete. The
12 mixture was diluted with H₂O (20 mL), the aqueous layer was extracted with DCM
13 (15 mL×2), the combined organic layer was washed with brine (20 mL×3), dried over
14 Na₂SO₄, filtered and the filtrate was concentrated under reduced pressure. The residue
15 was purified by column chromatography on silica gel, eluting with dichloromethane
16 /methanol solution to obtain the desire compound [58].

17

18 4.2.2.1. (Z)-2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-yl)-N-(
19 3-selenocyanatopropyl)acetamide (2a)[58]. Yield: 60%. White solid. Mp: 117-118°C.
20 ¹H NMR (400 MHz, CDCl₃): δ 2.06 (t, 2H, *J* = 4.00 Hz, CH₂), 2.23 (s, 3H, -CH₃),
21 2.82 (s, 3H, -CH₃), 2.97 (t, 2H, *J* = 4.00 Hz, CH₂), 3.38-3.42 (m, 2H, CH₂), 3.52 (s,
22 2H, -CH₂), 6.02 (brs, 1H, NH), 6.58-6.62 (m, 1H, ArH), 6.84 (d, 1H, *J* = 8.00Hz,
23 ArH), 7.18-7.21 (m, 2H, ArH), 7.68 (d, 2H, *J* = 8.00Hz, Ar-H), 7.75(d, 2H, *J* =
24 8.00Hz, Ar-H). ¹³C NMR (100 MHz, CDCl₃): δ 10.6, 27.1, 31.0, 33.7, 38.4, 43.9,
25 102.1 (-CN), 105.8 (d, *J*_{c-f} = 24.0 Hz), 111.3 (d, *J*_{c-f} = 22.0 Hz), 124.0 (d, *J*_{c-f} = 12.0
26 Hz), 129.0, 129.6 (d, *J*_{c-f} = 3.0 Hz), 130.3, 132.2 (d, *J*_{c-f} = 2.0 Hz), 138.9, 139.4, 141.4,
27 145.6, 146.2 (d, *J*_{c-f} = 9.0 Hz), 162.1, 164.6, 170.0. MS(ESI): m/z = found 524.9
28 ([M+Na]⁺); calcd. 524.5 [M+Na]⁺; HRMS calcd. For C₂₄H₂₃FN₂O₂SSe[M+H]⁺:
29 503.0699, found 503.0658 [M+H]⁺.

30

1 4.2.2.2. *2-(2-Fluoro-biphenyl-4-yl)-N-(2-selenocyanato-ethyl)-propionamide*
2 (**2b**)[58]. Yield: 62%. White solid. Mp: 88-90°C. ¹H NMR (400 MHz, CDCl₃): δ 1.53
3 (d, 3H, *J* = 4.00 Hz, -CH₃), 1.86-1.91 (m, 2H, -CH₂), 2.81 (t, 2H, *J* = 8.00 Hz, -CH₂),
4 3.26-3.30 (m, 2H, -CH₂), 3.59 (q, 1H, *J* = 4.00 Hz, -CH), 6.04 (s, 1H, -NH), 7.11-7.15
5 (m, 2H, ArH), 7.34-7.45 (m, 4H, ArH), 7.51-7.53 (m, 2H, ArH). ¹³C NMR (100 MHz,
6 CDCl₃): δ 18.5, 27.2, 31.1, 38.4, 46.6, 102.3 (-CN), 115.2 (d, *J*_{C-F} = 23.0 Hz), 123.5 (d,
7 *J*_{C-F} = 3.0 Hz), 127.8, 128.1 (d, *J*_{C-F} = 14.0 Hz), 128.5, 128.9 (d, *J*_{C-F} = 3.0 Hz), 131.2
8 (d, *J*_{C-F} = 3.0 Hz), 135.2, 142.4 (d, *J*_{C-F} = 7.0 Hz), 160.3 (d, *J*_{C-F} = 248.0 Hz), 174.4.
9 MS(ESI): *m/z* = found 413.0 ([M+Na]⁺); calcd. 412.3 [M+Na]⁺; HRMS calcd. For
10 C₁₉H₁₉FN₂OSe[M+H]⁺: 391.0717, found 391.0718 [M+H]⁺.

11

12 4.2.2.3. *2-(2,3-Dimethyl-phenylamino)-N-(2-selenocyanato-propyl)-benzamide*
13 (**2c**)[58]. Yield: 55%. White solid. Mp: 95-96°C. ¹H NMR (400 MHz, CDCl₃): δ 2.18
14 (s, 3H, -CH₃), 2.14-2.23 (m, 2H, -CH₂), 2.31 (s, 3H, -CH₃), 3.09 (t, 2H, *J* = 8.00 Hz,
15 -CH₂), 3.60 (q, 2H, *J* = 8.00 Hz, -CH₂), 6.54-6.56 (m, 1H, Ar-H), 6.68 (t, 1H, *J* = 8.00
16 Hz, ArH), 6.91 (d, 1H, *J* = 8.00 Hz, ArH), 6.95 (d, 1H, *J* = 8.00 Hz, ArH), 7.06 (t,
17 1H, *J* = 8.00 Hz, ArH), 7.13 (d, 1H, *J* = 8.00 Hz, ArH), 7.19-7.24 (m, 1H, ArH), 7.41
18 (d, 1H, *J* = 8.00 Hz, ArH), 9.10 (s, 1H, -NH). ¹³C NMR (100 MHz, CDCl₃): δ 14.1,
19 20.8, 27.6, 31.3, 38.5, 102.7(-CN), 115.2, 116.4, 117.1, 121.0, 125.9, 126.0, 127.6,
20 131.0, 132.7, 138.3, 139.5, 147.3, 170.5. MS(ESI): *m/z* = found 410.1 ([M+Na]⁺);
21 calcd. 409.3[M+Na]⁺; HRMS calcd. For C₁₉H₂₁N₃OSe [M+H]⁺: 388.0920, found
22 388.0917 [M+H]⁺.

23

24 4.2.2.4.

25 *2-[1-(4-Chloro-benzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-N-2(2-selenocyanato-pr*
26 *opyl)-acetamide (2d)*[58]. Yield: 65%. White solid. Mp: 101-102°C. ¹H NMR (400
27 MHz, CDCl₃): δ 2.03 (t, 2H, *J* = 8.00 Hz, -CH₂), 2.39 (s, 3H, -CH₃), 2.96 (t, 2H, *J* =
28 8.00 Hz, -CH₂), 3.35-3.39 (m, 2H, -CH₂), 3.64 (s, 2H, -CH₂), 3.82 (s, 3H, -OCH₃),
29 5.93 (brs, 1H, -NH), 6.68-6.71 (m, 1H, ArH), 6.83-6.86 (m, 2H, ArH), 7.47 (d, 2H, *J*
30 = 8.00 Hz, ArH), 7.63 (d, 2H, *J* = 8.00 Hz, ArH). ¹³C NMR (100 MHz, CDCl₃): δ 13.3,

1 27.2, 30.9, 32.2, 38.3, 55.8, 100.8, 102.1(-CN), 112.2, 112.5, 115.2, 129.2, 130.2,
2 131.0, 131.2, 133.5, 136.5, 139.6, 156.3, 168.4, 170.8. MS(ESI): m/z = found 526.0
3 ([M+Na]⁺); calcd. 525.9 [M+Na]⁺; HRMS calcd. For C₂₃H₂₂ClN₃O₃Se [M+H]⁺:
4 504.0585, found 504.0575 [M+H]⁺.

5
6 4.2.2.5. (*s*)-2-(3-Benzoyl-phenyl)-N-(2-selenocyanato-propyl)-propionamide (**2e**).
7 Yield: 65%. White solid. Mp: 87-89°C. ¹H NMR (400 MHz, CDCl₃): δ 1.53 (d, 3H, *J*
8 = 8.00 Hz, -CH₃), 2.02-2.06 (m, 2H, -CH₂), 2.96 (t, 2H, *J* = 8.00 Hz, -CH₂), 3.35-3.38
9 (m, 2H, -CH₂), 3.63 (q, 1H, *J* = 8.00 Hz, -CH), 5.96 (brs, 1H, -NH), 7.44-7.51 (m, 3H,
10 ArH), 7.56-7.61 (m, 3H, ArH), 7.74-7.79 (m, 3H, ArH). ¹³C NMR (100 MHz, CDCl₃):
11 δ 18.6, 27.2, 31.1, 38.4, 46.9, 102.3(-CN), 128.4, 128.9, 129.0, 129.3, 130.1, 131.4,
12 132.7, 137.3, 138.1, 141.7, 174.5, 196.6. MS(ESI): m/z = found 423.0 ([M+Na]⁺);
13 calcd.422.3 [M+Na]⁺; HRMS calcd. For C₂₀H₂₀N₂O₂Se [M+H]⁺: 401.0760, found
14 401.0765 [M+H]⁺.

15

16 4.2.2.6.(*S*)-2-(6-methoxynaphthalen-2-yl)-N-(3-selenocyanatopropyl)propanamide(**2f**)
17 [58].Yield: 75%. White solid. Mp: 96-98 °C. ¹H NMR (400 MHz, CDCl₃): δ 1.58 (d,
18 *J* = 8.00 Hz, 3H, -CH₃), 1.96-1.99 (m, 2H, -CH₂), 2.86-2.92 (m, 2H, -CH₂), 3.30-3.33
19 (m, 2H, -CH₂), 3.65-3.68 (q, *J* = 8.00 Hz, 1H, -CH), 3.91 (s, 3H, -OCH₃), 5.69 (brs,
20 1H, -NH), 7.12-7.18 (m, 2H, ArH), 7.35 (d, 1H, *J* = 8.00 Hz), 7.64 (s, 1H, ArH),
21 7.69-7.14 (m, 2H, ArH). ¹³C NMR (100 MHz, CDCl₃): δ 18.6, 27.3, 31.1, 38.3, 47.0,
22 55.4, 102.4(-CN), 105.7, 119.4, 126.0, 126.2, 127.7, 129.0, 129.2, 133.8, 136.2, 157.9,
23 175.3. MS(ESI): m/z = found 399.0 ([M+Na]⁺); calcd.399.1 [M+Na]⁺; HRMS calcd.
24 For C₁₈H₂₀N₂O₂Se[M+H]⁺: 377.0760, found 377.0759 [M+H]⁺.

25

26 4.2.2.7.

27 2-(1,8-Diethyl-1,3,4,9-tetrahydro-pyranol[3,4-*b*]indol-1-yl)-N-(3-selenocyanato-prop
28 yl)-acetamide (**2g**) [58]. Yield: 65%. White solid. Mp: 104-106 °C. ¹H NMR (400
29 MHz, CDCl₃): δ 0.92 (t, 3H, *J* = 8.00 Hz, -CH₃), 1.31 (t, 3H, *J* = 8.00 Hz, -CH₃),
30 1.87-1.97 (m, 2H, -CH₂), 2.08-2.17 (m, 2H, -CH₂), 2.40-2.44 (m, 1H, -CH), 2.79-2.88

1 (m, 5H, CH₂, CH₂, CH), 2.88-2.32 (m, 1H, -CH), 3.09-3.16 (m, 1H, -CH), 3.52-3.60
2 (m, 1H, -CH), 4.05-4.15 (m, 2H, -CH₂), 6.88 (brs, 1H, -NH), 7.00-7.02 (m, 1H, ArH),
3 7.05-7.09 (m, 1H, ArH), 7.33 (d, 1H, *J* = 8.00 Hz, ArH), 9.35 (brs, 1H, -NH). ¹³C
4 NMR (100 MHz, CDCl₃): δ 7.7, 14.2, 22.4, 24.1, 26.4, 31.1, 31.7, 37.9, 44.0, 60.4,
5 76.0, 102.4(-CN), 107.4, 115.8, 120.0, 120.9, 126.1, 127.0, 134.7, 135.8, 172.2.
6 MS(ESI): *m/z* = found 456.2 ([M+Na]⁺); calcd.456.1 [M+Na]⁺; HRMS calcd. For
7 C₂₁H₂₇N₃O₂Se[M+H]⁺: 434.1338, found 434.1302 [M+H]⁺.

8
9 4.2.2.8. 2-(4-isobutylphenyl)-N-(3-selenocyanatopropyl)propanamide (**2h**)[58]. Yield:
10 68%. White solid. Mp: 109-111°C. ¹H NMR (400 MHz, CDCl₃): δ 0.89 (d, 6H, *J* =
11 8.00 Hz, 2×-CH₃), 1.48 (d, 3H, *J* = 8.00 Hz, -CH₃), 1.81-1.87 (m, 1H, -CH),
12 1.98-2.03 (m, 2H, -CH₂), 2.44 (d, 1H, *J* = 4.00 Hz, -CH₂), 2.91 (td, 2H, *J* = 8.00 and
13 1.00 Hz, -CH₂), 3.29-3.34 (m, 2H, -CH₂), 3.49-3.54 (m, 1H, -CH), 5.72 (brs, 1H,
14 -NH), 7.11 (d, 2H, *J* = 8.00 Hz, ArH), 7.16 (d, 2H, *J* = 8.00 Hz, ArH). ¹³C NMR (100
15 MHz, CDCl₃): δ 18.3, 22.4, 27.3, 30.2, 31.1, 38.2, 45.0, 46.7, 102.4(-CN), 127.2,
16 129.8, 138.3, 141.0, 175.0. MS(ESI): *m/z* = found 353.0 ([M+H]⁺); calcd.353.1
17 [M+H]⁺; HRMS calcd. For C₁₇H₂₄N₂OSe[M+H]⁺: 353.1124, found 353.1129
18 [M+H]⁺.

19
20 4.2.2.9.2-((3-selenocyanatopropyl)carbamoyl)phenyl acetate (**2i**). Yield: 72%. White
21 solid. Mp: 72-74°C. ¹H NMR (400 MHz, CDCl₃): δ 2.13-2.19 (m, 2H, -CH₂), 2.32 (s,
22 3H, -CH₃), 3.10 (d, 2H, *J* = 8.00 Hz, -CH₂), 3.54-3.59 (m, 1H, -CH₂), 6.50 (brs, 1H,
23 -NH), 7.10 (d, 1H, *J* = 8.00 Hz, ArH), 7.27-7.29 (m, 1H, ArH), 7.31-7.50 (m, 1H,
24 ArH), 7.65 (d, 1H, *J* = 8.00 Hz, ArH). ¹³C NMR (100 MHz, CDCl₃): δ 21.2, 27.2,
25 31.2, 38.5, 102.4 (-CN), 123.2, 126.3, 128.1, 129.2, 132.1, 148.1, 166.8, 169.3.
26 MS(ESI): *m/z* = found 326.9 ([M+H]⁺); calcd. 327.0 [M+H]⁺; HRMS calcd. For
27 C₁₃H₁₄N₂O₃Se [M+H]⁺: 327.0240, found 327.0238 [M+H]⁺.

28
29 4.2.2.10.N-(3-selenocyanatopropyl)-2-((3-(trifluoromethyl)phenyl)amino)benzamide
30 (**2j**). Yield: 75%. White solid. Mp: 132-134 °C. ¹H NMR (400 MHz, CDCl₃): δ
31 2.13-2.19 (m, 2H, -CH₂), 2.32 (s, 3H, -CH₃), 3.10 (d, 2H, *J* = 8.00 Hz, -CH₂),

1 3.54-3.59 (m, 1H, -CH₂), 6.50 (brs, 1H, -NH), 7.10 (d, 1H, *J* = 8.00 Hz, ArH),
2 7.27-7.29 (m, 1H, ArH), 7.31-7.50 (m, 1H, ArH), 7.65 (d, 1H, *J* = 8.00 Hz, ArH). ¹³C
3 NMR (100 MHz, CDCl₃): δ 27.2, 31.1, 38.6, 102.1(-CN), 116.0, 116.4 (q, *J*_{C-F} = 4.0
4 Hz), 118.60 (m, *J*_{C-F} = 4.0 Hz), 119.2, 122.7, 123.1(q, *J*_{C-F} = 271 Hz, -CF₃), 127.5,
5 129.9, 131.6, 131.7 (q, *J*_{C-F} = 32 Hz), 132.7, 142.2, 144.5, 170.0. MS(ESI): *m/z* =
6 found 450.0 ([M+Na]⁺); calcd. 450.0 [M+Na]⁺; HRMS calcd. For C₁₈H₁₆F₃N₃OSe
7 [M+H]⁺: 428.0481, found 428.0483 [M+H]⁺.

8

9 4.2.3. General procedure for the synthesis of compounds **3a-3j**

10 To a solution of compound **2(a-j)** (300mg, 1.0eq.) in THF (10ml) was added
11 TBAF (1 eq.) and TMSCF₃ (10 eq.). The mixture was stirred at 25°C for 6 hours. TLC
12 showed the reaction was completed. The mixture was concentrated under reduced
13 pressure. The desire compound was purified by column chromatography on silica gel.

14

15 4.2.3.1. (*Z*)-5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-*N*-(3-(trifluoromethyls
16 elanyl)propyl)-1*H*-indene-3-carboxamide (**3a**). Yield: 72%. White solid. Mp:
17 134-136 °C. ¹H NMR (400 MHz, CDCl₃): δ 1.94-1.96 (m, 2H, -CH₂), 2.22 (s, 3H,
18 -CH₃), 2.82 (s, 3H, -CH₃), 2.89 (t, 2H, *J* = 8.00 Hz, -CH₂), 3.33-3.36 (m, 2H, -CH₂),
19 3.53(s, 2H, -CH₂), 5.76 (brs, 1H, -NH), 6.58-6.63 (m, 1H, ArH), 6.83-6.86 (m, 1H,
20 ArH), 7.18-7.20 (m, 1H, ArH), 7.21(s, 1H, CH), 7.68 (d, 2H, *J* = 8.00 Hz, ArH), 7.74
21 (d, 2H, *J* = 8.00 Hz, ArH). ¹³C NMR (100 MHz, CDCl₃): δ 10.6, 22.8, 30.2, 33.8, 39.1,
22 43.9, 105.9 (d, *J*_{C-F} = 24.0 Hz), 111.3 (d, *J*_{C-F} = 22.0 Hz), 122.5 (q, *J*_{C-F} = 313.0 Hz,
23 -SeCF₃), 123.9, 128.9, 129.5 (d, *J*_{C-F} = 3.0 Hz), 130.2, 132.3 (d, *J*_{C-F} = 2.0 Hz), 138.8,
24 139.4, 141.4, 145.8, 146.2 (d, *J*_{C-F} = 8.0 Hz), 163.4 (d, *J*_{C-F} = 246.0 Hz), 169.4. ¹⁹F
25 NMR (CDCl₃, 376 MHz): δ = -34.3 (s, -SeCF₃), -112.1 (s, F). MS(ESI): *m/z* = found
26 546.1 ([M+H]⁺); calcd. 546.1[M+H]⁺; HRMS calcd. For C₂₄H₂₃F₄NO₂SSe [M+H]⁺:
27 546.0621, found 546.0568 [M+H]⁺.

28

29 4.2.3.2. 2-(2-fluorobiphenyl-4-yl)-*N*-(3-(trifluoromethylselanyl)propyl)propanamide
30 (**3b**). Yield: 75%. White solid. Mp: 113-115 °C. ¹H NMR (400 MHz, CDCl₃): δ 1.55

1 (d, 3H, $J = 8.00$ Hz, -CH₃), 1.95-1.99 (m, 2H, -CH₂), 2.89-2.92 (m, 2H, -CH₂),
2 3.33-3.37 (m, 2H, -CH₂), 3.57 (q, 1H, $J = 8.00$ Hz, -CH), 5.51 (brs, 1H, -NH),
3 7.09-7.15 (m, 2H, ArH), 7.36-7.46 (m, 4H, ArH), 7.52-7.55 (m, 2H, ArH). ¹³C NMR
4 (100 MHz, CDCl₃): δ 18.5, 22.8, 30.4, 39.1, 46.7, 115.2, 115.2 (d, $J_{C-F} = 24$ Hz),
5 122.6 (q, $J_{C-F} = 329$ Hz, -SeCF₃), 127.8, 128.3 (d, $J_{C-F} = 13$ Hz), 128.5, 128.9 (d, J_{C-F}
6 = 3.0 Hz), 131.2 (d, $J_{C-F} = 4.0$ Hz), 135.3, 142.5 (d, $J_{C-F} = 7.0$ Hz), 159.9 (d, $J_{C-F} =$
7 250.0 Hz), 173.8. ¹⁹F NMR (CDCl₃, 376 MHz): $\delta = -34.3$ (s, -SeCF₃), -116.9 (s, F).
8 MS(ESI): $m/z =$ found 434.1 ([M+H]⁺); calcd. 434.1[M+H]⁺; HRMS calcd. For
9 C₁₉H₁₉F₄NOSe [M+H]⁺: 434.0638, found 434.0625 [M+H]⁺.

10

11 4.2.3.3. 2-(2,3-dimethylphenylamino)-N-(3-(trifluoromethylselenyl)propyl)benzamide
12 (**3c**). Yield: 75 %. White solid. Mp: 113-115 °C. ¹H NMR (400 MHz, CDCl₃):
13 δ 2.12-2.15 (m, 2H, -CH₂), 2.19 (s, 3H, -CH₃), 2.32 (s, 3H, -CH₃), 3.04-3.07 (m, 2H,
14 -CH₂), 3.55-3.60 (m, 2H, -CH₂), 6.26 (brs, 1H, -NH), 6.67-6.71 (m, 1H, ArH),
15 6.90-6.96 (m, 2H, ArH), 7.05-7.08 (m, 1H, ArH), 7.14-7.16 (m, 1H, ArH), 7.19-7.24
16 (m, 1H, ArH), 7.37-7.40 (m, 1H, ArH), 9.12 (brs, 1H, -NH). ¹³C NMR (100 MHz,
17 CDCl₃): δ 13.9, 20.7, 23.0, 30.6, 39.1, 115.0, 116.6, 116.8, 121.0, 124.9 (q, $J_{C-F} =$
18 301.0 Hz, -SeCF₃), 125.7, 125.8, 127.3, 130.9, 132.5, 138.1, 139.4, 147.2, 170.0. ¹⁹F
19 NMR (CDCl₃, 376 MHz): $\delta = -34.2$ (s, -SeCF₃). MS(ESI): $m/z =$ found 431.1
20 ([M+H]⁺); calcd. 431.1[M+H]⁺; HRMS calcd. For C₁₉H₂₁F₃N₂OSe [M+H]⁺: 431.0781,
21 found 431.0831 [M+H]⁺.

22

23 4.2.3.4.

24 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-N-(3-(trifluoromethylsela
25 nyl)propyl)acetamide (**3d**). Yield: 70 %. White solid. Mp: 162-164 °C. ¹H NMR (400
26 MHz, CDCl₃): δ 1.91-1.94 (m, 2H, -CH₂), 2.39 (s, 3H, -CH₃), 2.85-2.88 (m, 2H, -CH₂),
27 3.30-3.35 (m, 2H, -CH₂), 3.65 (s, 2H, -CH₂), 3.82 (s, 3H, -CH₃), 5.76 (brs, 1H, -NH),
28 6.69-6.72 (m, 1H, ArH), 6.84 (s, 1H, ArH), 6.86-6.87 (m, 1H, ArH), 7.50 (d, 2H, $J =$
29 8.00 Hz, ArH), 7.64 (d, 2H, $J = 8.00$ Hz, ArH). ¹³C NMR (100 MHz, CDCl₃): δ 13.2,
30 22.7, 30.3, 32.2, 39.0, 55.8, 100.7, 112.4, 112.6, 115.2, 122.5 (q, $J_{C-F} = 329.0$ Hz,

1 **-SeCF₃**), 129.3, 130.2, 130.9, 131.2, 133.5, 136.4, 139.7, 156.4, 168.4, 170.3. ¹⁹F
2 NMR (CDCl₃, 376 MHz): δ = -34.3 (s, -SeCF₃). MS(ESI): m/z = found 547.0
3 ([M+H]⁺); calcd. 547.0[M+H]⁺; HRMS calcd. For C₂₃H₂₂ClF₃N₂O₃Se [M+H]⁺:
4 547.0506, found 547.0470 [M+H]⁺.

5
6 4.2.3.5. 2-(3-Benzoyl-phenyl)-N-(3-trifluoromethylselanyl-propyl)-propionamide (**3e**).

7 Yield: 65 %. White solid. Mp: 101-103 °C. ¹H NMR (400 MHz, CDCl₃): δ 1.55 (d,
8 3H, *J* = 8.00 Hz, -CH₃), 1.93-1.96 (m, 2H, -CH₂), 2.86-2.90 (m, 2H, -CH₂), 3.31-3.34
9 (m, 2H, -CH₂), 3.62 (q, 1H, *J* = 8.00 Hz, -CH), 5.59 (brs, 1H, -NH), 7.44-7.51 (m, 3H,
10 ArH), 7.56-7.63 (m, 2H, ArH), 7.67 (d, 1H, *J* = 8.00 Hz, ArH), 7.74 (s, 1H, ArH),
11 7.79 (d, 2H, *J* = 8.00 Hz, ArH). ¹³C NMR (100 MHz, CDCl₃): δ 18.6, 22.8, 30.4, 39.0,
12 47.0, 122.6 (q, *J*_{C-F} = 328.0 Hz, -SeCF₃), 128.4, 128.8, 129.3, 130.0, 131.5, 132.7,
13 137.3, 138.1, 141.9, 174.1, 196.7. ¹⁹F NMR (CDCl₃, 376 MHz): δ = -34.3 (s, -SeCF₃).
14 MS(ESI): m/z = found 444.1 ([M+H]⁺); calcd. 444.1[M+H]⁺; HRMS calcd. For
15 C₂₀H₂₀F₃NO₂Se [M+H]⁺: 444.0681, found 444.0679 [M+H]⁺.

16
17 4.2.3.6.

18 (*S*)-2-(6-methoxynaphthalen-2-yl)-N-(3-(trifluoromethylselanyl)propyl)propanamide
19 (**3f**). Yield: 78 %. White solid. Mp: 127-129 °C. ¹H NMR (400 MHz, CDCl₃): δ 1.60
20 (d, 3H, *J* = 8.00 Hz, -CH₃), 1.86-1.93 (m, 2H, -CH₂), 2.83-2.86 (m, 2H, -CH₂),
21 3.27-3.32 (m, 2H, -CH₂), 3.69 (q, 1H, *J* = 8.00 Hz, -CH), 3.92 (s, 3H, -OCH₃), 5.46
22 (brs, 1H, -NH), 7.13-7.18 (m, 2H, ArH), 7.35 (dd, 1H, *J*₁ = 4.00Hz, *J*₂ = 8.00 Hz,
23 ArH), 7.65 (s, 1H, ArH), 7.72 (t, 2H, *J* = 8.00 Hz, ArH). ¹³C NMR (100 MHz, CDCl₃):
24 δ 18.3, 22.8, 30.4, 39.0, 47.1, 55.4, 105.7, 119.3, 122.6 (q, *J*_{C-F} = 328.0 Hz, -SeCF₃),
25 126.1, 126.2, 127.7, 129.0, 129.2, 133.8, 136.3, 157.9, 174.8. ¹⁹F NMR (CDCl₃, 376
26 MHz): δ = -34.4 (s, -SeCF₃). MS(ESI): m/z = found 420.1 ([M+H]⁺); calcd.
27 420.1[M+H]⁺; HRMS calcd. For C₁₈H₂₀F₃NO₂Se [M+H]⁺: 420.0681, found 420.0686
28 [M+H]⁺.

29

1 4.2.3.7.

2 2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-*b*]indol-1-yl)-*N*-(3-(trifluoromethylselanyl
3 *l*)propyl)acetamide (**3g**). Yield: 65 %. White solid. Mp: 187-189 °C. ¹H NMR (400
4 MHz, CDCl₃): δ 0.88 (t, 3H, *J* = 8.00 Hz, -CH₃), 1.31 (t, 3H, *J* = 8.00 Hz, -CH₃),
5 1.78-1.91 (m, 2H, -CH₂), 1.92-2.17 (m, 2H, -CH₂), 2.60-2.71 (m, 2H, -CH₂),
6 2.81-2.96 (m, 6H, 3 × -CH₂), 3.22-3.46 (m, 2H, -CH₂), 4.03-4.10 (m, 2H, -CH₂), 6.62
7 (brs, 1H, -NH), 7.00 (d, 1H, *J* = 8.00 Hz, ArH), 7.06 (t, 1H, *J* = 8.00 Hz, ArH), 7.33
8 (d, 1H, *J* = 4.00 Hz, ArH), 9.35 (brs, 1H, -NH). ¹³C NMR (100 MHz, CDCl₃): δ 7.7,
9 13.9, 22.4, 22.7, 24.1, 30.7, 30.9, 38.5, 44.4, 60.5, 75.8, 107.6, 115.7, 119.7, 120.5,
10 122.6 (q, *J*_{C-F} = 328.0 Hz, -SeCF₃), 126.2, 126.9, 134.8, 135.8, 171.5. ¹⁹F NMR
11 (CDCl₃, 376 MHz): δ = -34.3 (s, -SeCF₃). MS(ESI): *m/z* = found 477.1 ([M+H]⁺);
12 calcd. 477.1 [M+H]⁺; HRMS calcd. For C₂₁H₂₇F₃N₂O₂Se [M+H]⁺: 477.1260, found
13 477.1220 [M+H]⁺.

14

15 4.2.3.8. 2-(4-isobutylphenyl)-*N*-(3-(trifluoromethylselanyl)propyl)propanamide (**3h**).
16 Yield: 60 %. White solid. Mp: 108-110 °C. ¹H NMR (400 MHz, CDCl₃): δ 0.90 (d,
17 6H, *J* = 8.00 Hz, 2 × -CH₃), 1.51 (d, 3H, *J* = 8.00 Hz, -CH₃), 1.80-1.92 (m, 3H, -CH₂,
18 -CH), 2.46 (d, 2H, *J* = 8.00 Hz, -CH₂), 2.83-2.86 (m, 2H, -CH₂), 3.25-3.32 (m, 2H,
19 -CH₂), 3.52 (q, 1H, *J* = 8.00 Hz, -CH), 5.39 (brs, 1H, -NH), 7.12 (d, 2H, *J* = 8.00 Hz,
20 ArH), 7.17 (d, 2H, *J* = 8.00 Hz, ArH). ¹³C NMR (100 MHz, CDCl₃): δ 18.3, 22.4,
21 22.8, 30.2, 30.4, 38.9, 45.0, 46.8, 122.6 (q, *J*_{C-F} = 328.0 Hz, -SeCF₃), 127.3, 129.8,
22 138.4, 141.0, 174.9. ¹⁹F NMR (CDCl₃, 376 MHz): δ = -34.4 (s, -SeCF₃). MS(ESI):
23 *m/z* = found 396.1 ([M+H]⁺); calcd. 396.1 [M+H]⁺; HRMS calcd. For C₁₇H₂₄F₃NOSe
24 [M+H]⁺: 396.1045, found 396.1034 [M+H]⁺.

25

26 4.2.3.9. 2-(3-(trifluoromethylselanyl)propylcarbamoyl)phenyl acetate (**3i**). Yield:
27 78 %. White solid. Mp: 94-96 °C. ¹H NMR (400 MHz, CDCl₃): δ 2.04-2.12 (m, 2H,
28 -CH₂), 3.02-3.06 (m, 2H, -CH₂), 2.32 (s, 3H, -CH₃), 3.51-3.56 (m, 2H, -CH₂), 6.32
29 (brs, 1H, -NH), 7.10 (dd, 1H, *J*₁ = 4.00 Hz, *J*₂ = 8.00 Hz, ArH), 7.28-7.32 (m, 1H,
30 ArH), 7.45-7.49 (m, 1H, ArH), 7.68 (dd, 1H, *J*₁ = 4.00 Hz, *J*₂ = 8.00 Hz, ArH). ¹³C

1 NMR (100 MHz, CDCl₃): δ 21.1, 22.8, 30.6, 39.2, 122.7 (q, $J_{C-F} = 329.0$ Hz, -SeCF₃),
2 123.2, 126.3, 128.4, 129.3, 131.9, 148.0, 166.3, 169.2. ¹⁹F NMR (CDCl₃, 376 MHz):
3 $\delta = -34.2$ (s, -SeCF₃). MS(ESI): m/z = found 370.0 ([M+H]⁺); calcd. 370.0 [M+H]⁺;
4 HRMS calcd. For C₁₃H₁₄F₃NO₃Se [M+H]⁺: 370.0161, found 370.0158 [M+H]⁺.

5 6 4.2.3.10.

7 *2-(3-(trifluoromethyl)phenylamino)-N-(3-(trifluoromethylselenanyl)propyl)benzamide*

8 (**3j**). Yield: 63 %. White solid. Mp: 164-166 °C. ¹H NMR (400 MHz, CDCl₃): δ
9 2.10-2.17 (m, 2H, -CH₂), 3.03-3.07 (m, 2H, -CH₂), 3.54-3.59 (m, 2H, -CH₂), 6.29 (brs,
10 1H, -NH), 6.84-6.88 (m, 1H, ArH), 7.21-7.23 (m, 1H, ArH), 7.31-7.39 (m, 4H, ArH),
11 7.42-7.44 (m, 2H, ArH), 9.45 (brs, 1H, -NH). ¹³C NMR (100 MHz, CDCl₃): δ 22.9,
12 30.4, 39.2, 116.0, 116.2 (q, $J_{C-F} = 3.0$ Hz), 118.5 (q, $J_{C-F} = 4.0$ Hz), 119.0, 119.2,
13 122.6 (q, $J_{C-F} = 329.0$ Hz, -SeCF₃), 123.0, 124.0 (q, $J_{C-F} = 271.0$ Hz, -CF₃), 127.5,
14 129.9, 131.7 (q, $J_{C-F} = 32.0$ Hz), 132.5, 142.2, 144.3, 169.7. ¹⁹F NMR (CDCl₃, 376
15 MHz): δ -34.2 (s, -SeCF₃), -62.8 (s, PhCF₃). MS(ESI): m/z = found 471.0 ([M+H]⁺);
16 calcd. 471.0 [M+H]⁺; HRMS calcd. For C₁₈H₁₆F₆N₂OSe [M+H]⁺: 471.0402, found
17 471.0405 [M+H]⁺.

18

19 4.3. Cell lines and growth conditions

20 Exponentially growing cells were harvested and plated in 96-well plates at a
21 concentration of 1×10⁴ cells/well. After 24 h incubation at 37 °C under a humidified
22 5% CO₂ to allow cell attachment, the cells in the wells were respectively treated with
23 target compounds at various concentrations for 48 h. The concentration of DMSO was
24 always kept below 1.25%, which was found to be non-toxic to the cells. Three hours
25 prior to experiment termination, MTT solution (20 μ L of 5.0 mg/mL solution) was
26 added to each well and incubated at 37°C. At the termination time point, the
27 medium/MTT mixtures were removed, and the formazan crystals formed by the
28 mitochondrial dehydrogenase activity of vital cells were dissolved in 100 μ l of DMSO
29 per well. The optical densities were measured at 570 nm using a 96-well multiscanner
30 (Dynex Technologies, MRX Revelation; Chantilly, VA, USA).

1

2 4.4 Detection of Bcl-2, IL-2 and caspase-3 molecular biomarkers in MCF-7 cells

3 Bcl-2, IL-2 and caspase-3 cells were evaluated in MCF-7 cells treated with the
4 corresponding target compounds and incubated for 48 h and compared with their
5 levels in control untreated MCF-7 cell line [59]. The cells were harvested by
6 trypsinization and lysed by lysate buffer (Beyotime Biotech, Najing, China). Protein
7 levels of Bcl-2, IL-2 and caspase-3 were measured using enzyme-linked
8 immunosorbent assay (ELISA) by multifunctional enzyme marker (Molecular
9 Devices i3, USA) at a wavelength of 570 nm.

10

11 4.5. DPPH free radical scavenging activity

12 DPPH free radical scavenging activity of corresponding compounds was
13 measured according to the method as previous reported with little optimization[60].
14 Briefly, 20 mL of test samples at different concentrations was mixed with 180 mL of
15 or DPPH solution for 30 min in the dark. Then, the change in absorbance at 517 nm
16 for DPPH was measured on a microplate reader. Ascorbic acid (vitamin C) and
17 ebselen were used as a positive control, DMSO was used as a negative control.

18

19 4.6. Bleomycin-dependent DNA damage

20 The reaction mixture contained DNA (0.5 mg/mL), bleomycin sulfate
21 (0.05 mg/mL), MgCl₂ (5 mM), FeCl₃ (50 mM), and tested compound in a conc. of
22 0.1 mg/mL. L-ascorbic acid was used as positive control. The mixture was incubated
23 at 37°C for 1h. The reaction was terminated by addition of 0.05 mL EDTA (0.1 M).
24 The color was developed by adding 0.5 mL TBA (1% w/v) and 0.5 mL HCl (25% v/v),
25 followed by heating at 80°C for 30 minutes. After cooling in ice water, the extent of
26 DNA damage was measured by increase in absorbance at 532 nm [61].

27

28 4.7 Molecular Modeling

29 4.7.1 Protein and Ligand Preparation

1 The mammalian TrxR1 protein (PDB ID: 1H6V) used for docking was obtained
2 from Protein Data Bank. The original structure was prepared using Protein
3 Preparation Wizard in Maestro 11.5 (Schrödinger Release 2018-1: Maestro,
4 Schrödinger, LLC, New York, NY, 2018.), with all but one subunit (E) discarded,
5 bond orders assigned, hydrogens added, ionization and tautomerization state adjusted,
6 hydrogen bond assignment optimized, waters removed, and structure minimized.

7 The LigPrep utility in Maestro 11.5 was used to perform ligand preparation
8 applying OPLS3 force field. Generation of tautomers and possible ionization states
9 was mediated by Epik utility. All stereoisomers were considered to be generated,
10 followed by minimization of the resulting 3D conformations. There was no filtration
11 process during preparation.

12 13 4.7.2 Ligand Docking

14 The docking task was carried out in Discovery Studio 2018 (Dassault Systèmes
15 BIOVIA, Discovery Studio 2018, San Diego: Dassault Systèmes, 2018). The prepared
16 TrxR1 protein was typed in CHARMM force field and the docking site was defined as
17 a sphere with center coordinates X: 27.757, Y: 6.510, Z: 33.698 and a radius of 15 Å.
18 Using Flexible Docking protocol, the residue sidechains within the site sphere were
19 allowed to move. 10 protein conformations were created with a maximum alteration
20 of 8 residues. FAST method adopted, up to 25 conformations per ligand were
21 generated with an energy threshold of 20 kcal. With all other parameters as default,
22 ligands were preliminarily docked into each protein structure. After removal of
23 similar poses by clustering, the remaining complexes were refined and minimized,
24 leading to a total of 133 final poses.

25 26 4.7.3 Result Analysis

27 The resulting 133 poses were clustered by ligand (53 for 3h, 40 each for 2h and
28 3h) and visualized in Maestro 11.5. For each of the poses, the distance between the
29 compound's selenium atom and the sulfur atom of either Cys497 or Cys498 was
30 calculated as a measurement of covalent bonding probability. Any complex with less

1 than 5Å of the distance above was counted potentially reactive. For each ligand,
2 average –CDocker energy and average selenium-sulfur distance were calculated, the
3 latter was –CDocker energy weighted.

4

5 **Statistical analysis**

6 MTT data were given as mean ± SD of three independent experiments, graphs
7 and curve fitting were using origin Version 8.0 (OriginLab Corporation, Northampton,
8 USA). P value less than 0.05 was considered statistically significant.

9

10 **Acknowledgments**

11 This investigation was made possible through the financial support of National
12 Natural Science Foundation of China (Grant No: 21302065) and Shenzhen Fushan
13 Biological Technology Co., Ltd.

14

15 **References**

- 16 [1] H. Aljadhey, W. Tu, R.A. Hansen, S.J. Blalock, D.C. Brater, M.D. Murray,
17 Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on
18 blood pressure in patients with hypertension, BMC cardiovascular disorders. 12
19 (2012) 93.
- 20 [2] T. Benbow, J. Campbell, Microemulsions as transdermal drug delivery systems
21 for nonsteroidal anti-inflammatory drugs (NSAIDs): a literature review, Drug
22 Development and Industrial Pharmacy. 45(12) (2019): 1849-1855.
- 23 [3] T. Takiuchi, E. A. Blake, K. Matsuo, A.K. Sood, T.M. Brasky, Aspirin use
24 and endometrial cancer risk and survival, Gynecol. Oncol. 148 (1) (2018)
25 222–232.
- 26 [4] J. Podhorec, R. Hrstka, O. Bílek, Š. Tuček, J. Navrátil, E. Michalová, B. Vojtěšek,
27 Acetylsalicylic Acid and its Potential for Chemoprevention of Colorectal
28 Carcinoma. Klin Onkol. 31(Suppl 2) (2018) 77-81.
- 29 [5] W. Hao, Y. Shen, M. Feng, H. Wang, M. Lin, Y. Fang, L. Tan, Aspirin acts in
30 esophageal cancer: a brief review. J. Thorac. Dis. 10 (4) (2018) 2490–2497.

- 1 [6] A. Albin, B. Bassani, D. Baci, K. Dallaglio, M. Gallazzi, P. Corradino, A.
2 Bruno, D. M. Noonan, Nutraceuticals and "Repurposed" Drugs of Phytochemical
3 Origin in Prevention and Interception of Chronic Degenerative Diseases and
4 Cancer. *Curr. Med. Chem.* 26 (6) (2019) 973–987.
- 5 [7] S.R. Seshasai, S. Wijesuriya, R. Sivakumaran, S. Nethercott, S. Erqou, N. Sattar,
6 K.K. Ray, Effect of aspirin on vascular and nonvascular outcomes: meta-analysis
7 of randomized controlled trials, *Arch. Intern. Med.* 172 (3) (2012) 209–216.
- 8 [8] S.A. Johannesdottir, E.T. Chang, F. Mehnert, M. Schmidt, A.B. Olesen, H.T.
9 Sorensen, Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a
10 population-based case-control study, *Cancer* 118 (19) (2012) 4768–4776.
- 11 [9] S.K. Suthar, M. Sharma, Recent developments in chimeric NSAIDs as anticancer
12 agents: teaching an old dog a new trick. *Mini. Rev. Med. Chem.* 16 (15) (2016)
13 1201–1218.
- 14 [10] P. Norvaisas, D. Chan, K. Yokoi, B. Dave, A. Ziemys, The protein kinase
15 promiscuities in the cancer-preventive mechanisms of NSAIDs. *Eur. J. Cancer.*
16 *Prev.* 25 (1) (2016) 77–84.
- 17 [11] A.P. Fernandes, V.Gandin, Selenium compounds as therapeutic agents in cancer,
18 *Biochimica et Biophysica Acta.* 1850 (8) (2015) 1642-1660.
- 19 [12] P. Guo, Q. Wang, J. Liu, L. Liu, P. Zhao, Y. Cao, Y. Liu, C. Qi, Preparation of
20 two organoselenium compounds and their induction of apoptosis to SMMC-7221
21 cells, *Biol. Trace Elem. Res.* 154 (2) (2013) 304–311.
- 22 [13] D. Desai, U. Salli, K.E. Vrana, S. Amin, SelSA, selenium analogs of SAHA as
23 potent histone deacetylase inhibitors, *Bioorg. Med. Chem. Lett.* 20 (6) (2010)
24 2044-2047.
- 25 [14] J.T. Pinto, R. Sinha, K. Papp, N.D. Facompre, D. Desai, K. El-Bayoumy,
26 Differential effects of naturally occurring and synthetic organoselenium
27 compounds on biomarkers in androgen responsive and androgen independent
28 human prostate carcinoma cells. *Int. J. Cancer* 120 (7) (2007) 1410–1417.

- 1 [15] U. Singh, K. Null, R. Sinha, In vitro growth inhibition of mouse mammary
2 epithelial tumor cells by methylseleninic acid: involvement of protein kinases,
3 Mol. Nutr. Food Res. 52 (11) (2008) 1281–1288.
- 4 [16] A.K. Sharma, A. Sharma, D. Desai, S.V. Madhunapantula, S.J. Huh, G.P.
5 Robertson, S. Amin, Synthesis and anticancer activity comparison of phenylalkyl
6 isoselenocyanates with corresponding naturally occurring and synthetic
7 isothiocyanates, J. Med. Chem. 51 (24) (2008) 7820-7826.
- 8 [17] E. Moreno, D. Plano, I. Lamberto, M. Font, I. Encio, J.A. Palop, C. Sanmartin,
9 Sulfur and selenium derivatives of quinazoline and pyrido[2,3-d]pyrimidine:
10 synthesis and study of their potential cytotoxic activity in vitro, Eur. J. Med.
11 Chem. 47 (3) (2012) 283-298.
- 12 [18] L. Engman, I. Cotgreave, M. Angulo, C.W. Taylor, G.D. Paine-Murrieta, G.
13 Powis, Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and
14 potential antitumor agents, Anticancer Res. 17 (6D) (1997) 4599–4605.
- 15 [19] A. Ghose, J.Fleming, K. El-Bayoumy, P.R. Harrison, Enhanced sensitivity of
16 human oral carcinomas to induction of apoptosis by selenium compounds:
17 involvement of mitogen-activated protein kinase and Fas pathways, Cancer Res.
18 61 (20) (2001) 7479-7487.
- 19 [20] C. Hansch, A. Leo, R.W. Taft, A survey of Hammett substituent constants and
20 resonance and field parameters, Chem. Rev. 91 (2) (1991) 165–195.
- 21 [21] C. Hansch, A. Leo, Substituent Constant for Correlation Analysis in Chemistry
22 and Biology, Wiley, New York (USA), 1979.
- 23 [22] C. Ghiazza, A. Tlili, T. Billard, Electrophilic trifluoromethylselenolation of
24 boronic acids, Molecules. 22 (5) (2017) 833.
- 25 [23] W. Fang, T. Dong, J. Han, G. Zha, C. Zhang, Expedient
26 trifluoromethylthiolation and trifluoromethylselenolation of alkynyl (phenyl)
27 iodoniums by $[XCF_3]^-$ ($X = S, Se$) anions, Org. Biomol. Chem. 14 (48) (2016)
28 11502–11509.
- 29 [24] S. Potash, S. Rozen, General synthesis of trifluoromethyl selenides utilizing
30 selenocyanates and fluoroform, J. Org. Chem. 79 (22) (2014) 11205–11208.

- 1 [25] P. Nikolaienko, M. Rueping, Trifluoromethylselenolation of aryldiazonium salts:
2 a mild and convenient copper-catalyzed procedure for the Introduction of the
3 SeCF₃ group, *Chem. Eur. J.* 22 (8) (2016) 2620-2623.
- 4 [26] Q. Glenadel, E. Ismalaj, T. Billard, Benzyltrifluoromethyl (or fluoroalkyl)
5 selenide: reagent for electrophilic trifluoromethyl (or fluoroalkyl) selenolation,
6 *J. Org. Chem.* 81 (18) (2016) 8268–8275.
- 7 [27] D. Desai, I. Sinha, K. Null, W. Wolter, M.A. Suckow, T. King, S. Amin, R. Sinha,
8 Synthesis and antitumor properties of selenocoxib-1 against rat prostate
9 adenocarcinoma cells, *Int. J. Cancer.* 127 (1) (2010) 230–238.
- 10 [28] D. Plano, D.N. Karelia, M. K. Pandey, J.E. Spallholz, S. Amin, A.K. Sharma,
11 Design, synthesis, and biological evaluation of novel selenium (Se-NSAID)
12 molecules as anticancer agents, *J. Med. Chem.* 59 (5) (2016) 1946–1959.
- 13 [29] S. Ficht, L. Röglin, M. Ziehe, D. Breyer, O. Seitz, Direct carbodiimide-mediated
14 conjugation of carboxylates using pyridinium p-toluenesulfonate and tertiary
15 amines as additives, *Synlett.* 14 (2004) 2525-2528.
- 16 [30] M. Ben Dahman Andaloussi, F. Mohr, The chemistry of trityl isoselenocyanate
17 revisited: a preparative and structural investigation, *J. Organomet. Chem.* 695 (9)
18 (2010) 1276–1280.
- 19 [31] T. Billard, S. Large, B.R. Langlois, Preparation of trifluoromethyl sulfides or
20 selenides from trifluoromethyl trimethylsilane and thiocyanates or
21 selenocyanates, *Tetrahedron Letters.* 38 (1) (1997) 65-68.
- 22 [32] R. Gowda, S. V. Madhunapantula, D. Desai, S. Amin, G. P. Robertson,
23 Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit
24 melanoma, *Mol. Cancer Ther.* 12 (2013) 3–15.
- 25 [33] A.K. Sharma, A. Sharma, D. Desai, S.V. Madhunapantula, S.J. Huh, G.P.
26 Robertson, S. Amin, Synthesis and anticancer activity comparison of phenylalkyl
27 isoselenocyanates with corresponding naturally occurring and synthetic
28 isothiocyanates, *J. Med. Chem.* 51 (24) (2008) 7820–7826.
- 29 [34] O.A. Tomashenko, V.V. Grushin, Aromatic trifluoromethylation with metal
30 complexes, *Chem Rev.* 111 (8) (2011) 4475-4521.

- 1 [35] S. Shaaban, A. Negm, A.M. Ashmawy, D.M. Ahmed, L.A. Wessjohann, Combi-
2 natorial synthesis, in silico, molecular and biochemical studies of tetrazole-
3 derived organic selenides with increased selectivity against hepatocellular
4 carcinoma, *Eur. J. Med. Chem.* 122 (2016) 55-71.
- 5 [36] S. Mecklenburg, S. Shaaban, L.A. Ba, T. Burkholz, T. Schneider, B. Diesel, A.K.
6 Kiemer, A. Roseler, K. Becker, J. Reichrath, A. Stark, W. Tilgen, M. Abbas, L.A.
7 Wessjohann, F. Sasse, C. Jacob, Exploring synthetic avenues for the effective
8 synthesis of selenium- and tellurium-containing multifunctional redox agents,
9 *Org. Biomol. Chem.* 7 (22) (2009) 4753-4762.
- 10 [37] J.T. Pinto, R. Sinha, K. Papp, N.D. Facompre, D. Desai, K. El-Bayoumy,
11 Differential effects of naturally occurring and synthetic organoselenium
12 compounds on biomarkers in androgen responsive and androgen independent
13 human prostate carcinoma cells, *Int. J. Cancer.* 120 (2007) 1410-1417.
- 14 [38] V. Jamier, L.A. Ba, C. Jacob, Selenium-and tellurium-containing multifunctional
15 redox agents as biochemical redox modulators with selective cytotoxicity,
16 *Chemistry-A European Journal.* 16 (36) (2010) 10920-10928.
- 17 [39] D.Pathania, M.Sechi, M. Palomba, V Sanna, F. Berrettini, A. Sias, L.Taheri,
18 N.Neamati, Design and discovery of novel quinazolinedione-based redox
19 modulators as therapies for pancreatic cancer, *BBA-GEN. SUBJECTS.* 1840
20 (1) (2014) 332-343.
- 21 [40] D. Plano, Y. Baquedano, E Ibáñez, I. Jiménez, J.A. Palop, J.E. Spallholz, C.
22 Sanmartín, Antioxidant-prooxidant properties of a new organoselenium
23 compound library, *Molecules.* 15 (10) (2010) 7292-312.
- 24 [41] S. Shaaban, A.M. Ashmawy, A. Negm, L.A. Wessjohann, Synthesis and
25 biochemical studies of novel organic selenides with increased selectivity for
26 hepatocellular carcinoma and breast adenocarcinoma, *Eur. J. Med. Chem.* 179
27 (2019) 515-526.
- 28 [42] I. Lagunes, P. Begines, A. Silva, A.R. Galán, A. Puerta, M.X. Fernandes, I. Maya,
29 J.G. Fernández-Bolaños, Ó. López, J.M. Padrón, Selenocoumarins as new

- 1 multitarget antiproliferative agents: Synthesis, biological evaluation and in silico
2 calculations, *Eur. J. Med. Chem.* 179 (2019) 493-501.
- 3 [43] D. Meriane, G. Genta-Jouve, M. Kaabeche, S. Michel, S. Boutefnouchet, Rapid
4 identification of antioxidant compounds of *Genista saharae* coss. & dur. By
5 combination of DPPH scavenging assay and HPTLC-MS, *Molecules*. 19 (4)
6 (2014) 4369-4379.
- 7 [44] R. Uddin, M.R. Saha, N. Subhan, H. Hossain, I.A. Jahan, R. Akter, A. Alam,
8 HPLC-analysis of polyphenolic compounds in *gardenia jasminoides* and
9 determination of antioxidant activity by using free radical scavenging assays,
10 *Adv. Pharmaceut. Bull.* 4 (3) (2014) 273-281.
- 11 [45] D. Huang, B. Qu, R.L. Prior, The chemistry behind antioxidant capacity assays, *J.*
12 *Agric. Food Chem.* 53 (6) (2005) 1841–1856.
- 13 [46] X. Tian, K.M. Schaich, Effects of molecular structure on kinetics and dynamics
14 of the trolox equivalent antioxidant capacity assay with ABTS(t*), *J. Agric. Food*
15 *Chem.* 61 (23) (2013) 5511-5519.
- 16 [47] M. Ibrahim, W. Hassan, J. Anwar, A.M. Deobald, J.P. Kamdem, D.O. Souza, J.B.
17 Rocha, 1-(2-(2-(2-(1-Aminoethyl)phenyl)diselanyl)phenyl)ethanamine: an amino
18 organoselenium compound with interesting antioxidant profile, *Toxicol. In. Vitro.*
19 28 (4) (2014) 524-530.
- 20 [48] A. Mira, E.M. Gimenez, A.D. Bolzan, M.S. Bianchi, D.M. Lopez-Larraza,
21 Effect of thiol compounds on bleomycin-induced DNA and chromosome
22 damage in human cells, *Arch. Environ. Occup. Health.* 68 (2) (2013) 107-116.
- 23 [49] A. Mira, E.M. Gimenez, A.D. Bolzan, M.S. Bianchi, D.M. Lopez-Larraza,
24 Effect of thiol compounds on bleomycin-induced DNA and chromosome
25 damage in human cells, *Arch. Environ. Occup. Health.* 68 (2) (2013) 107-116.
- 26 [50] B. Laffon, V. Valdiglesias, E. Pásaro, J. Méndez. The Organic selenium
27 compound selenomethionine modulates bleomycin-induced DNA damage and
28 repair in human leukocytes, *Biol. Trace. Elem. Res.* 133 (1) (2010) 12–19.
- 29 [51] V. Nascimento, E.E. Alberto, D.W. Tondo, D. Dambrowski, M.R. Detty, F.
30 Nome, A.L. Braga, GPx-like activity of selenides and selenoxides: experimental

- 1 evidence for the involvement of hydroxy perhydroxy selenane as the active
2 species, *J. Am. Chem. Soc.* 134(1) (2012) 138-141.
- 3 [52] C.W. Nogueira, J.B.T. Rocha, Toxicology and pharmacology of selenium:
4 emphasis on synthetic organoselenium compounds. *Arch. Toxicol.* 85 (11) (2011)
5 1313-1359.
- 6 [53] A.S. Hodage, P.P. Phadnis, A. Wadawale, K.I. Priyadarsini, V.K. Jain, Synthesis,
7 characterization and structures of 2-(3,5-dimethylpyrazol-1-yl)ethylseleno
8 derivatives and their probable glutathione peroxidase (GPx) like activity, *Org.*
9 *Biomol. Chem.* 9 (8) (2011) 2992-2998.
- 10 [54] V. Nascimento, E.E. Alberto, D.W. Tondo, D. Dambrowski, M.R. Detty, F.
11 Nome, A.L. Braga, GPx-Like activity of selenides and selenoxides: experimental
12 evidence for the involvement of hydroxy perhydroxy selenane as the active
13 species, *J. Am. Chem. Soc.* 134 (1) (2012) 138-141.
- 14 [55] L.Wang, Z. Yang, J. Fu, H. Yin, K. Xiong, Q. Tan, H. Jin, J. Li, T. Wang, W.
15 Tang, J. Yin, G. Cai, M. Liu, S. Kehr, K. Becker, H. Zeng, Ethaselen: a potent
16 mammalian thioredoxin reductase 1 inhibitor and novel organoselenium
17 anticancer agent, *Free Radic. Biol. Med.* 52 (5) (2012) 898-908.
- 18 [56] S. Shaaban, A. Negm, A.M. Ashmawy, D.M. Ahmed, L.A. Wessjohann,
19 Combinatorial synthesis, in silico, molecular and biochemical studies of
20 tetrazole-derived organic selenides with increased selectivity against
21 hepatocellular carcinoma, *Eur. J. Med. Chem.* 122 (2016) 55-71.
- 22 [57] K. Kolšek, C. Aponte-Santamaría, F. Gräter, Accessibility explains preferred
23 thiol-disulfide isomerization in a protein domain, *Sci, Rep.* 7 (2017) 9858.
- 24 [58] L. Liu, S. Li, X. Li, M. Zhong, Y. Lu, J. Yang, Y. Zhang, X. He, Synthesis of
25 NSAIDs-Se derivatives as potent anticancer agents, *Med. Chem. Res.* 27 (2018)
26 2071-2078.
- 27 [59] R.M. Nowar, E.E. A.Osman, , S.M. Abou-Seri, S.M. El Moghazy, D.A. Abou El
28 Ella, Design, synthesis and biological evaluation of some novel quinazolinone

- 1 derivatives as potent apoptotic inducers, *Future. Med. Chemistry.* 10 (10)
2 (2018) 1191-1205.
- 3 [60] A.R. Verma, M. Vijayakumar, C.V. Rao, C.S. Mathela, In vitro and in
4 vivo antioxidant properties and DNA damage protective activity of green fruit
5 of *Ficus glomerata*, *Food. Chem. Toxicol.* 48 (2) (2010) 704-709.
- 6 [61] A.B.A. El-Gazzar, M.M. Youssef, A.M.S. Youssef, A.A. Abu-Hashem, F.A.
7 Badria, Design and synthesis of azolopyrimidoquinolines, pyrimidoquinazolines
8 as anti-oxidant, anti-inflammatory and analgesic activities, *Eur. J. Med. Chem.*
9 44 (2009) 609–624.
- 10
11